UBS initiates Ensysce Biosciences stock with buy on pain therapy potential

UBS has initiated coverage on Ensysce Biosciences Inc. (NASDAQ:ENSC) with a positive outlook, giving the company a "buy" rating and a price target of $2.00 per share. This target is notably higher than Ensysce's current stock price of $0.36, suggesting significant upside potential. Despite carrying a market capitalization of just $7 million, UBS views the company as an early-stage but differentiated opportunity in chronic pain treatment.

The firm's lead program, CY200, targets complex regional pain syndrome, a severe condition with no approved therapies. Ensysce's CY200 employs a unique combination of psychedelic compounds to treat pain at the brain and nervous system level, aiming for durable pain relief that remains long after dosing. With approximately 200,000 patients in the U.S. and about 50,000 new cases annually, the potential market for CY200 appears substantial.

UBS has modeled a potential peak sales value of $1.2 billion for the therapy, contingent on the treatment's success. The upcoming Phase 2a study is deemed a critical clinical event, with interim results anticipated in mid-2027 and the final results expected by Q4 2027. UBS acknowledges ongoing clinical risks, but believes the potential benefits could offer an attractive risk/reward ratio if the treatment proves effective.

The analysis highlights that Ensysce's shares have dropped 82.5% over the past year, and the company is rapidly consuming cash, which is a crucial factor for investors considering this early-stage opportunity. For those interested in a deeper analysis, InvestingPro provides 13 additional tips and comprehensive financial metrics for Ensysce.

Additionally, Ensysce is set to undergo changes in its executive leadership and board of directors during its upcoming annual stockholder meeting on December 14, 2026. Board member Will Chang intends to resign after the meeting, though he has yet to formally step down or set a departure date. These leadership changes, disclosed via a recent SEC filing, may influence the company's strategic direction, a factor that investors should consider. This report was AI-assisted and reviewed by a human editor to ensure accuracy and clarity.